Study of carvedilol on safety and effect in patients with congestive heart failure (CHF)

Objective: The purpose of the study was to evaluate the effect and safety of carvedilol in patients with CHF (NYHA classⅡ - Ⅳ). Methods: A total of 20 patients with CHF were treated with carvedilol at the beginning dose of 5mg/d and then slowly increased to 40mg/d as tolerated or to the dose can be just tolerated. At the same time, adverse events and results were evaluated. Results: After carvedilol therapy, (l)The NYHA class,index of myocardial oxygen consumption, SV, LVEDd, walk testing of 6 minutes ameliorated significantly (P0. 05), LVEF, LVFS increased very significantly (P0. 01), the mean dose of carvedilol was 29. 25±7. 46 mg/d; (2) Level of superoxide dismutase (SOD) increased (P0. 05), malondialdehyde (MDA) decreased (P0. 05) ; (3) There were 47 adverse events (mainly contain asthenia, dizzy, hypotension) happen at low dose or un-tolerated period, no serious adverse event happen. Conclusion: Carvedilol possesses good effects and safety in patients with CHF.